The Different Expression of BRAFV600E Mutation in Patients with Papillary Thyroid Carcinomas Coexisting with or without Benign Thyroid Nodules
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: BRAFV600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC) and has been associated with poor prognostic factors. The purpose of the present study is to investigate the frequency of the BRAF mutation in PTC with and without benign thyroid nodules (BN). Methods: 98 DNA samples were extracted from frozen tissues of 51 PTC and 47 BN specimens of 70 patients and were divided into four group: PTC with BN, PTC alone, BN with PTC and BN alone group. We investigated the BRAF mutation by sequencing and clinicopathologic characteristics. Results: Total positive rate of BRAF mutation was 23.5% in the two PTC groups. That rate of the PTC with BN group was 10.7% and the PTC alone group was 39.1%. Positive rate in the PTC with BN group was lesser than the PTC alone group and had statistically difference (P=0.02). The positive rate of BRAF mutation was 7.1% in the BN with PTC group and 5.3% in the BN alone group. Positive rate in these two group was not statistically different (P=0.80). Conclusion: The frequency of BRAF mutation in PTC with concurrent BN was lower than in PTC alone. This result suggests that the effect of BRAF mutation is lesser associated with PTCs with BN than PTC alone group.
Abstract
Purpose: BRAFV600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC) and has been associated with poor prognostic factors. The purpose of the present study is to investigate the frequency of the BRAF mutation in PTC with and without benign thyroid nodules (BN). Methods: 98 DNA samples were extracted from frozen tissues of 51 PTC and 47 BN specimens of 70 patients and were divided into four group: PTC with BN, PTC alone, BN with PTC and BN alone group. We investigated the BRAF mutation by sequencing and clinicopathologic characteristics. Results: Total positive rate of BRAF mutation was 23.5% in the two PTC groups. That rate of the PTC with BN group was 10.7% and the PTC alone group was 39.1%. Positive rate in the PTC with BN group was lesser than the PTC alone group and had statistically difference (P=0.02). The positive rate of BRAF mutation was 7.1% in the BN with PTC group and 5.3% in the BN alone group. Positive rate in these two group was not statistically different (P=0.80). Conclusion: The frequency of BRAF mutation in PTC with concurrent BN was lower than in PTC alone. This result suggests that the effect of BRAF mutation is lesser associated with PTCs with BN than PTC alone group.
참고문헌 (24)
- O'Neill CJ, "BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer", Surgery, 148, pp.1139~1145 (2010)
- Welker MJ, "Thyroid nodules", Am Fam Physician, 67, pp.559~566 (2003)
- Mekel M, "Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules", Am J Surg, 200, pp.136~143 (2010)
- Kim SK, "Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules", Diagn Mol Pathol, 17, pp.118~125 (2008)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Nucera C, "Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E)", Biochim Biophys Acta, 1795, pp.152~161 (2009)
- Xing M, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28, pp.742~762 (2007)
- Kim SK, "Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis", Thyroid, 19, pp.137~141 (2009)
- Knauf JA, "Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation", Cancer Res, 65, pp.4238~4245 (2005)
- Kim SK, "Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status", J Clin Endocrinol Metab, 96, pp.658~664 (2011)
- Adeniran AJ, "Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study", Thyroid, 21, pp.717~723 (2011)
- Wagieh SM, "Impact of histopathology of non-neoplastic thyroid tissue on ablation outcome in patients with papillary thyroid cancer", Nucl Med Commun, 32, pp.597~604 (2011)
- Arora N, "Do benign thyroid nodules have malignant potential? An evidence-based review", World J Surg, 32, pp.1237~1246 (2008)
- Bradly DP, "Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases", Surgery, 146, pp.1099~1104 (2009)
- Cerci C, "Thyroid cancer in toxic and non-toxic multinodular goiter", J Postgrad Med, 53, pp.157~160 (2007)
- Park SH, "A histopathologic study on 1,095 surgically resected thyroid specimens", Jpn J Clin Oncol, 18, pp.297~302 (1988)
- Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma", Clin Endocrinol (Oxf), 63, pp.588~593 (2005)
- Kuma K, "Fate of untreated benign thyroid nodules: results of long-term follow-up", World J Surg, 18, pp.495~498 (1994)
- Kebebew E, "Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited", World J Surg, 25, pp.632~637 (2001)
- Loh KC, "Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma", J Clin Endocrinol Metab, 84, pp.458~463 (1999)
- Fiore E, "Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role", Endocr Relat Cancer, 16, pp.1251~1260 (2009)
- Haymart MR, "Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage", J Clin Endocrinol Metab, 93, pp.809~814 (2008)
- Mardente S, "Cross-talk between NO and HMGB1 in lymphocytic thyroiditis and papillary thyroid cancer", Oncol Rep, 24, pp.1455~1461 (2010)
- Pellegriti G, "Outcome of differentiated thyroid cancer in Graves' patients", J Clin Endocrinol Metab, 83, pp.2805~2809 (1998)